
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care is poised for long-term success with their diverse product portfolio, strong revenue growth potential, and focus on the pharmacy sales channel. Despite short-term challenges, their pipeline of new products, such as the Mobi Tubeless insulin pump, showcase their commitment to innovation and potential for continued market dominance. With a clear strategy and strong financials, Tandem Diabetes Care is a promising company with a positive outlook for the future.
Bears say
Tandem Diabetes Care is facing several headwinds, including a challenging competitive landscape, limited traction with new product launches, and potential switch-outs of existing patients from its pumps. The company's transition to a pay-as-you-go ("Pay-Go") model in the pharmacy channel could also impede its scale and profitability. Additionally, the success of their new Mobi pump may take longer than expected to materialize, which could hinder their profit expansion. Risks to the downside include possible competitive headwinds and limited traction with new product launches, as well as the company's ability to secure favorable contracts in the pharmacy channel. On the upside, Tandem may see success with accessing the pharmacy channel and can play more offense with new product cycles, which could lead to greater market share and faster profit growth. However, the company's outlook for 2026 and beyond remains uncertain due to potential headwinds and uncertainties surrounding their new product launches and pay-as-you-go model.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares